Focal segmental glomerulosclerosis (FSGS)
Drug research and approvals for focal segmental glomerulosclerosis (FSGS): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 31 studies of focal segmental glomerulosclerosis (FSGS) are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 31
- Trials authorized in Canada: 9
- FDA orphan approvals: 1
- EU medicines: 0
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected…NCT07614477 · Phase 2 · Everest Medicines (China) Co.,Ltd. · starts May 20, 2026
- SLIT ABS: Study on Patients With Autoimmune PodocytopathyNCT07516964 · Not applicable · Meyer Children's Hospital IRCCS · starts Jun 10, 2025
- A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental GlomerulosclerosisNCT07499700 · Phase 2 / Phase 3 · Bio-Thera Solutions · starts Oct 26, 2025
- A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)NCT07268638 · Phase 2 · Akebia Therapeutics · starts Dec 3, 2025
- A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental…NCT07220083 · Phase 3 · Boehringer Ingelheim · starts Feb 16, 2026
- A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisNCT07213960 · Phase 2 / Phase 3 · Apellis Pharmaceuticals, Inc. · starts Dec 1, 2026
- Raman Spectroscopy Diagnosis of Kidney DiseasesNCT06760845 · Not reported · Zunsong Wang · starts Feb 1, 2021
- An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte DiseasesNCT06664814 · Phase 2 · National Human Genome Research Institute (NHGRI) · starts Oct 27, 2026
Phase 3 7
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- IrbesartanType-1 angiotensin II receptor antagonist
- SparsentanEndothelin receptor ET-A antagonist
- DexamethasoneGlucocorticoid receptor agonist
- ChlorambucilDNA inhibitor
- CyclosporineCyclophilin A modulator
- CorticotropinMelanocortin receptor 2 agonist
Phase 2 12 of 21
- RituximabB-lymphocyte antigen CD20 binding agent
- Galactose
- AdalimumabTNF-alpha inhibitor
- IlacirnonC-C chemokine receptor type 2 antagonist
- FresolimumabTransforming growth factor beta-1 inhibitor
- Inaxaplin
- IsotretinoinRetinoic acid receptor agonist
- LisinoprilAngiotensin-converting enzyme inhibitor
- LosartanType-1 angiotensin II receptor antagonist
- SirolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- BasiliximabInterleukin-2 receptor inhibitor
Phase 1 or earlier 4
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- CyclophosphamideDNA inhibitor
- PamrevlumabConnective tissue growth factor inhibitor
How its trials ended
87 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 26% met their primary endpoint, 17% missed it and 57% stopped early.
- Completed, result not reported3237%
- Ongoing2832%
- Met its primary endpoint67%
- Stopped: other or unclear67%
- Missed its primary endpoint45%
- Status unknown45%
- Stopped: enrollment or feasibility33%
- Stopped: lack of efficacy22%
- Stopped: sponsor or business decision22%
| Nov 5, 2025 | A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor bi 764198 taken over a 104 week…BI 764198 | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Sep 26, 2024 | A parallel-group treatment, phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of…Frexalimab (SAR441344) / Rilzabrutinib (SAR444671) / Brivekimig (SAR442970) | Sanofi-Aventis Canada Inc | Ongoing |
| Mar 26, 2020 | An open label, intra-subject dose escalation study of CCX140 b in subjects with primary focal segmental glomerulosclerosis (FSGS) and nephrotic syndromeCCX140-B | Amgen | Pending |
| Jun 19, 2018 | A randomized, multicenter, double-blind, parallel, active-control study of the effects of sparsentan, a dual endothelin receptor and angiotensin receptor…Sparsentan (RE-021) | Travere Therapeutics | Closed |
| Apr 17, 2018 | A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety and efficacy of CCX140-b in subjects with focal segmental…CCX140-B | Amgen | Closed |
| Feb 13, 2018 | An adaptive, phase 2 trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-0670512 following multiple injections in adult subjects…PF-06730512 | Pfizer | Ongoing |
| Jun 29, 2017 | A phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of bleselumab in preventing the recurrence of focal…ASKP1240 (bleselumab) | Astellas Pharma | Closed |
| Apr 12, 2017 | Treatment of proteinuria due to treatment resistant or treatment intolerant idiopathic focal segmental glomerulosclerosis: a 2-part prospective study of h.p.…H.p. acthar gel | Mallinckrodt | Closed |
| Nov 13, 2013 | Study of losmapimod to reduce proteinuria in corticosteroid or calcineurin inhibitor resistant idiopathic focal segmental glomerulosclerosis (FSGS)Losmapimod (GW856553) | GSK | Ongoing |
| Apr 13, 2026 | FilspariTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without… | Travere Therapeutics, Inc. | Approved |
| Sep 12, 2018 | 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbo…Treatment of focal segmental glomerulosclerosis | ChemoCentryx, Inc. | Designated |
| Dec 9, 2015 | Propagermanium and irbesartanTreatment of focal segmental glomerulosclerosis. | Dimerix Bioscience Ltd. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA